|
Name |
Sarocladilactone A
|
| Molecular Formula | C31H42O8 | |
| IUPAC Name* |
[6-hydroxy-17-[6-(2-hydroxypropan-2-yl)-2-oxooxan-3-ylidene]-4,8,10,14-tetramethyl-3,7-dioxo-5,6,9,11,12,13,15,16-octahydro-4H-cyclopenta[a]phenanthren-16-yl]acetate
|
|
| SMILES |
CC(=O)OC1CC2(C)C(CCC3C4(C)C=CC(=O)C(C)C4C(O)C(=O)C32C)C1=C1CCC(C(C)(C)O)OC1=O
|
|
| InChI |
InChI=1S/C31H42O8/c1-15-19(33)12-13-29(5)21-10-9-18-23(17-8-11-22(28(3,4)37)39-27(17)36)20(38-16(2)32)14-30(18,6)31(21,7)26(35)25(34)24(15)29/h12-13,15,18,20-22,24-25,34,37H,8-11,14H2,1-7H3/b23-17-/t15-,18+,20+,21+,22+,24-,25+,29-,30+,31-/m1/s1
|
|
| InChIKey |
GWXVBOPCGHPLPP-BIGPXKPTSA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 542.67 | ALogp: | 3.5 |
| HBD: | 2 | HBA: | 8 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 127.2 | Aromatic Rings: | 5 |
| Heavy Atoms: | 39 | QED Weighted: | 0.392 |
| Caco-2 Permeability: | -4.942 | MDCK Permeability: | 0.00001970 |
| Pgp-inhibitor: | 1 | Pgp-substrate: | 0.007 |
| Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.222 |
| 30% Bioavailability (F30%): | 0.885 |
| Blood-Brain-Barrier Penetration (BBB): | 0.963 | Plasma Protein Binding (PPB): | 80.85% |
| Volume Distribution (VD): | 0.484 | Fu: | 23.27% |
| CYP1A2-inhibitor: | 0.006 | CYP1A2-substrate: | 0.116 |
| CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.798 |
| CYP2C9-inhibitor: | 0.071 | CYP2C9-substrate: | 0.071 |
| CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.111 |
| CYP3A4-inhibitor: | 0.508 | CYP3A4-substrate: | 0.391 |
| Clearance (CL): | 3.171 | Half-life (T1/2): | 0.116 |
| hERG Blockers: | 0 | Human Hepatotoxicity (H-HT): | 0.108 |
| Drug-inuced Liver Injury (DILI): | 0.327 | AMES Toxicity: | 0.011 |
| Rat Oral Acute Toxicity: | 0.507 | Maximum Recommended Daily Dose: | 0.809 |
| Skin Sensitization: | 0.033 | Carcinogencity: | 0.042 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
| Respiratory Toxicity: | 0.36 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003780 | ![]() |
0.577 | D0X7XG | ![]() |
0.301 | ||
| ENC003846 | ![]() |
0.557 | D09WYX | ![]() |
0.289 | ||
| ENC005154 | ![]() |
0.525 | D0D2TN | ![]() |
0.283 | ||
| ENC005236 | ![]() |
0.525 | D0W2EK | ![]() |
0.269 | ||
| ENC003847 | ![]() |
0.522 | D02JNM | ![]() |
0.265 | ||
| ENC001480 | ![]() |
0.479 | D04SFH | ![]() |
0.265 | ||
| ENC005487 | ![]() |
0.469 | D0F7NQ | ![]() |
0.265 | ||
| ENC005155 | ![]() |
0.460 | D08IWD | ![]() |
0.262 | ||
| ENC003484 | ![]() |
0.459 | D0K7HU | ![]() |
0.260 | ||
| ENC005153 | ![]() |
0.433 | D0D1SG | ![]() |
0.259 | ||